Table III.

Meta-analysis of retrospective cohort studies: effect of antenatal indomethacin (AI) on neonatal outcomes

Neonatal Outcome	Reference	# Infants exposed to AI	# Infants unexposed to AI	Random-effects Odds ratio (95% C.I)	Heterogeneity Test p-value
IVH	23,25,26, 28,29,31, 32,33,35, 37,41	730	834	1.25 (0.79 – 1.97)	0.003
Grade III–IV IVH	23,25,28, 29,30,31, 32,33, 35,36,37	775	1261	1.48 (0.83 – 2.6)	0.003
PVL	31,35,37	239	247	1.9 (1.01 – 3.58)	0.9
NEC	23,25,27, 28,29,31, 32,33,35, 36	733	1847	1.43 (0.84 – 2.43)	0.06
BPD	23,26,28, 31,41	164	177	1.17 (0.65 – 2.1)	0.25
PDA	22,23,26, 27,28,29, 31,32,33, 35,36,37, 41	835	1996	0.96 ( 0.75 – 1.23)	0.11
RDS	22,23,25, 26,27,29, 31,35,37,41	604	1323	1.08 (0.67 – 1.74)	0.001
Mortality	22,23,25, 26,29,31, 32,35,36, 37,41	708	1234	1.08 (0.72 – 1.63)	0.06